NASDAQ:ABMD - ABIOMED Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$370.04 +3.84 (+1.05 %)
(As of 10/24/2018 01:00 AM ET)
Previous Close$366.20
Today's Range$350.25 - $373.25
52-Week Range$164.80 - $459.75
Volume459,496 shs
Average Volume632,231 shs
Market Capitalization$16.26 billion
P/E Ratio151.04
Dividend YieldN/A
Beta0.03
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
Previous Symbol
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.49
Quick Ratio5.76

Price-To-Earnings

Trailing P/E Ratio151.04
Forward P/E Ratio106.95
P/E Growth3.87

Sales & Book Value

Annual Sales$593.75 million
Price / Sales27.97
Cash Flow$2.8401 per share
Price / Cash130.29
Book Value$15.57 per share
Price / Book23.77

Profitability

EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins25.71%
Return on Equity18.91%
Return on Assets16.64%

Miscellaneous

Employees1,143
Outstanding Shares44,880,000
Market Cap$16.26 billion
OptionableN/A

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) released its quarterly earnings results on Thursday, July, 26th. The medical equipment provider reported $1.95 EPS for the quarter, topping the consensus estimate of $0.80 by $1.15. The medical equipment provider had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. ABIOMED's revenue for the quarter was up 35.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 EPS. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for ABIOMED.

How can I listen to ABIOMED's earnings call?

ABIOMED will be holding an earnings conference call on Thursday, November 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8552122361.

What price target have analysts set for ABMD?

8 Wall Street analysts have issued twelve-month target prices for ABIOMED's shares. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's stock price to reach $374.00 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Price Targets for ABIOMED.

What is the consensus analysts' recommendation for ABIOMED?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)
  • Dr. David M. Weber, Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Mr. Ian McLeod, VP & Corp. Controller

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (1.42%), Scout Investments Inc. (0.28%), Strs Ohio (0.25%), Nisa Investment Advisors LLC (0.14%), Rhenman & Partners Asset Management AB (0.12%) and Bank of Montreal Can (0.11%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which institutional investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Rhenman & Partners Asset Management AB, Sumitomo Mitsui Asset Management Company LTD, Sheets Smith Wealth Management, Strs Ohio, Dorsey Wright & Associates, Jaffetilchin Investment Partners LLC and Texas Permanent School Fund. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.

Which institutional investors are buying ABIOMED stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Bank of Montreal Can, Nisa Investment Advisors LLC, Handelsbanken Fonder AB, EFG Asset Management Americas Corp., Aperio Group LLC, First Hawaiian Bank and Oakbrook Investments LLC. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $370.04.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $16.26 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

What is ABIOMED's official website?

The official website for ABIOMED is http://www.abiomed.com.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  326 (Vote Underperform)
Total Votes:  724
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/24/2018 by MarketBeat.com Staff

Featured Article: Tariff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel